Investigational drug · Phase 3
Mezagitamab
Also called: TAK-079
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Immune Thrombocytopenic Purpura (ITP), Antibody-Mediated Rejection (AMR), Kidney Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
9
Any phase or sponsor naming "Mezagitamab"
First trial start
2025
Feb 27, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Mezagitamab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Immune Thrombocytopenic Purpura (ITP)
- Antibody-Mediated Rejection (AMR)
- Kidney Disease
Approved drugs for the same conditions: Hematology and blood cancers · Cardiovascular and metabolic · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Mezagitamab" as an intervention, largest first.
- A Study of Mezagitamab in Adults With Kidney Condition Called IgA NephropathyPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT06963827 · 347 participants (planned) · Start Jul 15, 2025 · Primary completion Sep 7, 2028
Drug: Mezagitamab; Placebo · For: Kidney Disease
Sites: Birmingham, Alabama; Montgomery, Alabama; Surprise, Arizona · 186 sites in all
- A Study of Mezagitamab in Adults With Chronic Primary Immune ThrombocytopeniaPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT06722235 · 171 participants (planned) · Start Feb 27, 2025 · Primary completion Mar 16, 2028
Drug: Mezagitamab; Placebo · For: Immune Thrombocytopenic Purpura (ITP)
Sites: Hot Springs, Arkansas; Los Angeles, California; San Diego, California · 124 sites in all
- A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune ThrombocytopeniaPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT06948318 · 150 participants (planned) · Start Aug 14, 2025 · Primary completion Jul 29, 2029
Drug: Mezagitamab · For: Immune Thrombocytopenic Purpura (ITP)
Sites: Hot Springs, Arkansas; Los Angeles, California; San Diego, California · 118 sites in all
Millennium Pharmaceuticals, Inc.Takeda (TAK)
NCT03439280 · 50 participants · Start Apr 20, 2018 · Primary completion Jan 28, 2022
Drug: Mezagitamab; Pomalidomide and 1 more · For: Relapsed/Refractory; Multiple Myeloma
Sites: Duarte, California; St Louis, Missouri; New York, New York · 7 sites in all
TakedaTakeda (TAK)
NCT03984097 · 50 participants · Start Jul 29, 2019 · Primary completion Mar 25, 2026
Drug: TAK-079; Lenalidomide and 3 more · For: Multiple Myeloma
Sites: Birmingham, Alabama; Monterey, California; Bethesda, Maryland · 9 sites in all
TakedaTakeda (TAK)
NCT07613359 · 36 participants (planned) · Start Oct 27, 2026 · Primary completion Jan 15, 2029
Drug: Mezagitamab; Placebo · For: Antibody-Mediated Rejection (AMR)
Sites: Los Angeles, California; San Francisco, California; Miami, Florida · 35 sites in all
TakedaTakeda (TAK)
NCT04159805 · 36 participants · Start Jan 14, 2020 · Primary completion Jul 12, 2022
Drug: TAK-079; TAK-079 Placebo · For: Myasthenia Gravis
Sites: Tucson, Arizona; Palo Alto, California; Sacramento, California · 50 sites in all
TakedaTakeda (TAK)
NCT04776018 · 27 participants · Start Apr 20, 2021 · Primary completion Aug 2, 2023
Drug: TAK-981; Mezagitamab and 1 more · For: Relapsed and/or Refractory Multiple Myeloma (RRMM)
Sites: Scottsdale, Arizona; Jacksonville, Florida; Atlanta, Georgia · 13 sites in all
TakedaTakeda (TAK)
NCT05174221 · 17 participants · Start Aug 16, 2022 · Primary completion Dec 15, 2025
Drug: Mezagitamab · For: Kidney Disease; Glomerulonephritis
Sites: Northridge, California; Nampa, Idaho; Evanston, Illinois · 26 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Clinical Trial of Open-Label Mezagitamab in IgAN: Final 96-Week Results.
Barratt J, Kim DK, Park I, et al. · Kidney Int Rep 2027
- Targeting plasma cells for treatment of immune thrombocytopenia.
Mishra M, Song AB, Al-Samkari H · Blood Vessel Thromb Hemost 2026
- A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia.
Kuter DJ, Miura K, Patriarca A, et al. · N Engl J Med 2026
- Evolving understandings for the roles of CD38 protein in autoimmunity and autoimmune disease.
Ye X, Zhang J, Song M, et al. · Clin Exp Immunol 2026
- Antigen masking indirect antiglobulin test can mitigate the interference of Mezagitamab, a novel anti-CD38 antibody, in serological pre-transfusion testing.
Habicht CP, Schneeweiss C · Transfus Med 2025
- Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed/refractory multiple myeloma.
Krishnan AY, Patel KK, Mohan M, et al. · Blood Neoplasia 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Takeda.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.